Scholarlink

Aims <p>Direct oral anticoagulants (DOACs) are widely used for stroke prevention in people with non-valvular atrial fibrillation/flutter (NVAF).Anticoagulants have different bleeding profiles. Apixaban is associated with the lowest bleeding risk. This study evaluates the interaction between DOAC use and right ventricular systolic pressure (RVSP) on echocardiogram and bleeding rates. It was hypothesized that elevated RVSP may be associated with excess bleeding based on anticoagulant-specific pharmacologic profiles.</p> Methods&amp; Results <p>A retrospective analysis of a database was conducted. Multivariable regression models for bleeding rates were developed using an analysis approach that adjusts for confounders among participants who had undergone an echocardiogram, and interaction terms for DOAC choice were incorporated. Stratum-specific estimates were calculated using linear computation.</p> <p>Patients taking apixaban had lower bleeding rates than those taking rivaroxaban and dabigatran. Among those without elevated RVSP, there was no difference in bleeding rates. Where RVSP was ≥45mmHg, there was a 90% increase in bleeding rates with use of dabigatran (HR 1.99, p=0.024) and rivaroxaban (HR 1.86, p=0.042) compared to apixaban (Table 1D).</p> Conclusions <p>Elevated RVSP is associated with excess bleeding in patients taking rivaroxaban and dabigatran, but not apixaban, after controlling for confounding variables.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Echocardiographic hemodynamics correlate with differences in DOAC-specific bleeding and stroke rates in non-valvular atrial fibrillation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Michael P. O’Shea,
  • Ali Yusuf,
  • Eiad Habib,
  • Srekar Ravi,
  • Suganya Arunachalam Karikalan,
  • Chieh Ju Chao,
  • Hasan Ashraf,
  • Pradyumna Agasthi,
  • Sam Newton,
  • Robert L. Scott,
  • Timothy Barry,
  • Chadi Ayoub,
  • Reza Arsanjani,
  • Hicham El Masry

摘要

Aims

Direct oral anticoagulants (DOACs) are widely used for stroke prevention in people with non-valvular atrial fibrillation/flutter (NVAF).Anticoagulants have different bleeding profiles. Apixaban is associated with the lowest bleeding risk. This study evaluates the interaction between DOAC use and right ventricular systolic pressure (RVSP) on echocardiogram and bleeding rates. It was hypothesized that elevated RVSP may be associated with excess bleeding based on anticoagulant-specific pharmacologic profiles.

Methods& Results

A retrospective analysis of a database was conducted. Multivariable regression models for bleeding rates were developed using an analysis approach that adjusts for confounders among participants who had undergone an echocardiogram, and interaction terms for DOAC choice were incorporated. Stratum-specific estimates were calculated using linear computation.

Patients taking apixaban had lower bleeding rates than those taking rivaroxaban and dabigatran. Among those without elevated RVSP, there was no difference in bleeding rates. Where RVSP was ≥45mmHg, there was a 90% increase in bleeding rates with use of dabigatran (HR 1.99, p=0.024) and rivaroxaban (HR 1.86, p=0.042) compared to apixaban (Table 1D).

Conclusions

Elevated RVSP is associated with excess bleeding in patients taking rivaroxaban and dabigatran, but not apixaban, after controlling for confounding variables.